Genelux Corporation is a privately-held, clinical stage biopharmaceutical company that has developed a proprietary oncolytic virus based technology platform and a deep pipeline of products with broad applications for cancer detection and therapy.

GL-ONC1 the company’s lead oncology product candidate is an attenuated vaccina virus (Lister strain) that results in dramatic regression and elimination of a wide range of solid tumors in animals without damaging healthy tissues or organs. GL-ONC1 encodes Green Fluorescent Protein (GFP) to enable highly selective imaging of tumors and metastases as an aid in the diagnosis and staging of cancer. GL-ONC1 currently under evaluation in Phase I/II human clinical trials in the United States and Europe, and additional US and European-based trials are set to begin in the near future. GL-ONC1 is proving well-tolerated with minimal side effects and showing early signs of anti-tumor activity.

The company’s R&D efforts and leadership in the field of Oncolytic Virotherapy have yielded a wide variety of new applications for its platform and imaging technologies, including:

Genelux is headquartered in California, with additional operations in Germany.